From their prior statements, that doesn't seem at all likely to occur during this earnings announcement. Certainly, since it is their intention to remain on the market at least until further discussion with the FDA they are not going to pull it anytime soon.
one of the things that jumps out is that at the current cash burn rate, their money lasts well into 2008, and that's without any further expense reductions.
Four noted topics in press release:
-- The results of the Company's recent research study in which improvements to its technology demonstrated sensitivity in stool in excess of 80% for detecting colorectal cancer [nice to see them sticking with this, hopefully the science is as sound as their stated conviction on this]
-- Quarterly accession growth [sounds like they are projecting sales growth, that would be nice, if they are, hope there is some evidence]
-- 2006 focus [pretty much no what that is, would be nice to hear of some progress with acs and cms, at least whether there is any clarity about what needs to be accomplished, a check list of sorts]
-- Regulatory update. [hopefully no bombs]
No predictions here other than I think there is more likely than not that there is little negative, though there might be little immediately viewed as positive.
Looks like EXAS mgmt not backing down on QTLY growth expectations.
ie no product pulled off market. 'just the opposite !
Short covering big time tomorrow !
The following will be among the topics discussed on the Company's conference call on January 24, 2006 at 8:30 a.m. ET:
The results of the Company's recent research study in which improvements to its technology demonstrated sensitivity in stool in excess of 80% for detecting colorectal cancer; Quarterly accession growth; 2006 focus and Regulatory update.